title: Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.
abstract: The mainstay of initial therapy of metastatic prostate cancer has not changed since 1941 when Huggins and Hodges described the efficacy of castration. The benefit of combining an androgen receptor blocker with medical castration has been debatable despite several large randomized trials and meta-analyses intended to answer the question. Recent phase III trial data with continuous versus intermittent androgen deprivation in newly diagnosed metastatic prostate cancer have established continuous therapy as the preferred approach at the present time. Novel and more potent inhibitors of androgen signaling have been developed in the past 5 years and have been validated in castration-resistant disease. Their role in management of hormone-sensitive metastatic prostate cancer is under evaluation in ongoing studies. As androgen deprivation therapy carries significant long-term toxicities including fatigue and loss of bone and muscle mass, an important element of clinical management is prevention and amelioration of these toxicities.
authors: Ajjai
authors: A
authors: Alva
authors: Maha
authors: M
authors: Hussain
mesh_terms: D059002:Androgen Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery / Q000628:therapy; D011944:Receptors, Androgen / Q000378:metabolism
chemical_list: D059002:Androgen Receptor Antagonists; D000728:Androgens; D011944:Receptors, Androgen
references: Lancet. 2000 Apr 29;355(9214):1491-8
references: 10801170
references: NCI Monogr. 1988;(7):165-70
references: 3050535
references: J Urol. 2011 Mar;185(3):848-54
references: 21239017
references: J Clin Oncol. 2008 Dec 20;26(36):5936-42
references: 19029421
references: Prog Urol. 1996 Feb;6(1):17-22
references: 8624523
references: Urology. 2001 Apr;57(4):727-32
references: 11306391
references: Eur Urol. 2012 Jan;61(1):11-25
references: 21871711
references: Urology. 2000 Dec 20;56(6):1021-4
references: 11113751
references: Eur Urol. 2006 Jan;49(1):54-8; discussion 58
references: 16314038
references: BJU Int. 2010 Mar;105(5):648-51
references: 19747358
references: Horm Res. 1983;18(1-3):18-27
references: 6411578
references: J Urol. 1997 Jul;158(1):160-3
references: 9186345
references: Eur Urol. 1998;33(2):144-51
references: 9519355
references: Ann Oncol. 2004 Jun;15(6):974-8
references: 15151957
references: J Clin Oncol. 2012 Sep 10;30(26):3271-6
references: 22649143
references: Rev Urol. 2009 Spring;11(2):52-60
references: 19680526
references: Br J Urol. 1997 Feb;79(2):235-46
references: 9052476
references: Ann Oncol. 2009 Mar;20(3):542-9
references: 19129205
references: Lancet Oncol. 2010 Feb;11(2):147-54
references: 19963436
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Oncologist. 2012;17(9):1171-9
references: 22836449
references: Urology. 2004 Dec;64(6):1177-81
references: 15596193
references: J Clin Endocrinol Metab. 2012 Nov;97(11):4156-65
references: 22942386
references: Trends Endocrinol Metab. 2009 Jan;20(1):43-50
references: 19008119
references: Cancer. 2003 Mar 15;97(6):1507-16
references: 12627516
references: J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
references: 11121466
references: N Engl J Med. 1998 Oct 8;339(15):1036-42
references: 9761805
references: J Urol. 2002 Sep;168(3):1001-4
references: 12187208
references: Urology. 2011 May;77(5):1172-6
references: 21334731
references: J Clin Oncol. 2006 Aug 20;24(24):3984-90
references: 16921051
references: BJU Int. 2008 Dec;102(11):1531-8
references: 19035858
references: N Engl J Med. 2013 Apr 4;368(14):1314-25
references: 23550669
references: Anticancer Drugs. 2011 Mar;22(3):299-302
references: 21360851
references: BJU Int. 2005 Nov;96(7):1014-8
references: 16225519
references: Urology. 2003 Dec 22;62(6 Suppl 1):3-12
references: 14706503
references: Prostate Cancer Prostatic Dis. 2009;12(1):88-93
references: 18574490
references: N Engl J Med. 2009 Aug 20;361(8):745-55
references: 19671656
references: Lancet Oncol. 2013 Feb;14(2):149-58
references: 23306100